GSK plc

GSK plc P/CF

The P/CF (Price-to-Cash-Flow Ratio) of GSK plc (GSK.L) as of Oct 18, 2026 is 11.96. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 13.33 — a change of -10.26% (lower).

P/CF

11.96

YoY

-10.26%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of GSK plc is 2025 11.96 . P/CF (Price-to-Cash-Flow Ratio) of GSK plc was 2024 13.33 . It decreases by -10.26% lower compared to the previous year.

The GSK plc P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
10.37 GBP
Jan 1, 2019
10.89 GBP
Jan 1, 2020
10.35 GBP
Jan 1, 2021
10.99 GBP
Jan 1, 2022
11.80 GBP
Jan 1, 2023
12.91 GBP
Jan 1, 2024
13.33 GBP
Jan 1, 2025
11.96 GBP
The GSK plc P/CF history
YEARP/CFYoY
11.96-10.26%
13.33+3.27%
12.91+9.38%
11.80+7.42%
10.99+6.15%
10.35-4.99%
10.89+5.00%
10.37-17.85%
12.63-6.09%
13.45-60.46%
34.00+101.48%
16.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GSK plc Stock analysis

What does GSK plc do? GSK plc, listed on the London Stock Exchange under the ticker GSK.L, is a pharmaceutical company headquartered in Brentford, United Kingdom. The company, which has been publicly traded since May 22, 1972, operates within the healthcare sector, specifically in the pharmaceuticals industry. GSK employs 94,066 full-time staff, focusing on the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. The company's operations are structured around two primary segments: Pharmaceuticals and Vaccines. In the Pharmaceuticals segment, GSK develops and markets medicines for a variety of conditions, including respiratory diseases, HIV and infectious diseases, immuno-inflammation, oncology, and rare diseases. The Vaccines segment provides immunization solutions for all age groups, from infants to the elderly, including pediatric, adolescent, adult, and travel vaccines. GSK's portfolio includes prescription medicines and vaccines, with a particular emphasis on respiratory and HIV-related treatments. The company's business strategy encompasses both innovative therapeutic areas and established product lines, supporting its global presence in healthcare. GSK's official website is www.gsk.com, offering further information about its products and initiatives. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

P/CF (Price-to-Cash-Flow Ratio) of GSK plc is 11.96 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of GSK plc changed from 13.33 to 11.96, representing a -10.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — GSK plc

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — GSK plc